Immune checkpoint inhibitor resistance in hepatocellular carcinomaZhijie Wang, Jin Ding, Peng Gao et al.|Cancer Letters|2022Cited by 174
Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trialHuijie Bian, Ye Zhang, Ke Dong et al.|Signal Transduction and Targeted Therapy|2021Cited by 66